• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Stock Trend Alerts

Essential Market Ideas and Investing Strategies

  • Newsletter Reviews
  • Hot Stocks
  • Technology
  • Financial News
  • Secrets of the Pros
  • Analysis
Home » How the Delta Variant Fight Will Unleash a Wave of Genomics Innovation

How the Delta Variant Fight Will Unleash a Wave of Genomics Innovation

Here we go again…

Just when we thought the pandemic was over and it would be just a matter of time before life returned to normal, the delta variant comes along.

We’re now in the middle of a third wave of COVID-19. With the seven-day average of reported infections running at more than 100,000 as of August 6, we’re now back to February levels. In some areas, such as my current home state of Florida, hospitalizations are hitting new highs, and ICU beds are filling up … again.

According to CDC reports, the delta variant is as contagious as chickenpox. So, it’s hard to see this slowing down any time soon.

None of this is good news, of course. All we can do is be careful and hope for the best.

Delta Variant Fight Will Unleash a Wave of Innovation

If the past year and a half have taught us anything, it’s that the U.S. biotech sector is remarkably adept at finding solutions and finding them quickly.

Pfizer Inc. (NYSE: PFE) and Moderna Inc. (Nasdaq: MRNA) both introduced new mRNA vaccines within about a year of the initial virus outbreak in China and they did it using technology that had never been used before. Add to that the logistical efforts to distribute the vaccines to hundreds upon hundreds of millions of people around the world… There has truly never been anything like it.

I’m betting that the delta variant will unleash another wave of innovation in the tech sector. Moderna is already testing a COVID-19 booster shot that triggered a promising immune response against the highly contagious variant.

[Hot New Tech: This odd-looking machine could be the most transformative innovation in history]

This ties into a much broader theme that I consider the single most powerful investment trend of the next several decades. I’m not speaking in hyperbole when I say that genomics — or DNA-based medicine — is potentially bigger than the internet in terms of its overall investment potential.

It goes far beyond medicine.

Genomics Has Limitless Potential

As an example of some of the commercial potential for DNA science, consider that Microsoft (Nasdaq: MSFT) — yes, the company best known for Windows and Office — has made major investments in DNA storage development. We’re not talking about storing your DNA in a test tube. Microsoft and its partners want to replace your computer’s hard drive (or, more accurately, the storage drives of large data centers).

Microsoft had this to say about the project:

Demand for data storage is growing exponentially, but the capacity of existing storage media is not keeping up. Most of the world’s data today is stored on magnetic and optical media [i.e., a hard drive]. Despite improvements in optical discs, storing a zettabyte of data would still take many millions of units and use significant physical space.

If we are to preserve the world’s data, we need to seek significant advances in storage density and durability. Using DNA to archive data is an attractive possibility because it is extremely dense (up to about 1 exabyte per cubic millimeter) and durable (half-life of over 500 years).

Microsoft notes that we’re reaching the end of the line of existing silicon-based computer tech. We’ve taken that technology as far as it can go, so the time has come to incorporate biomolecules into computer design.

This is the stuff of science fiction … except it’s real and happening today.

[Discover: The off the radar Small-Cap Stock at the center of an Era-Defining Technology]

Genomics goes beyond making innovative vaccines. This has the potential to rival the microchip and the Industrial Revolution itself. It will shape the world we live in.

You could play this trend by buying Microsoft or by buying a broad ETF such as the ARK Genomic Revolution ETF (NYSE: ARKG). ARKG is a collection of stocks that have incorporated genomics into their businesses and is managed by storied tech investor Cathie Wood.

You could also check out our very own Green Zone Fortunes. I’ve identified genomics as the biggest mega-trend of the next decade. “Imperium,” the technology behind my No. 1 Genomics stock, will lead the way. It is poised to be bigger than electric vehicles, artificial intelligence and the internet-of-things.

The truth is, multiple industries are using this DNA-based technology to innovate. And we’re taking advantage of this mega trend in Green Zone Fortunes. Watch my presentation here to find out how you can join my readers on four different genomics stock recommendations today.

To good profits,

Adam O’Dell
Chief investment strategist, Money & Markets

Read more from Adam O'Dell at MoneyAndMarkets.com

You Might Also Like...

  • The Bullish Side of The Great Supply Chain Snarl
  • The Untold Secret of The World's Most Valuable Company...
  • Does the Massive Hype of Next Week's Robinhood IPO Outweigh the Risk?
  • Could This Be One of the Best Crypto Buying Opportunities of the Year?

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Subscribe to Stock Trend Alerts

By submitting your email address, you give Stock Trend Alerts permission to deliver investment research to your email inbox. Privacy Policy | How It Works

Popular Posts

  • Martin Weiss Docket No. OP–1670: 12 Inflation-Beating Stocks
  • Jim Rickards – The Return of American Energy: Profit from the Green Lie
  • Andrew Zatlin: Biden’s Puppet Master Exposed and How to Opt Out of the Digital Dollar
  • Why 2023 Could Kick Off a “Cash Frenzy” in Stocks
  • Dylan Jovine 21st Century Battlefield: 4 Companies Changing Warfare
  • Infinite Energy Stock: The Tiny Company Dominating Tesla in the Trillion-Dollar Green Energy Race
  • Dylan Jovine Search & Destroy: 3 AI Software Stocks Revolutionizing Warfare
  • BREAKING: Military to spend billions on “Living Missile”

Recent Posts

  • 25 Super-Woke Companies You Do Not Want in Your Portfolio with Alexander Green
  • Jeff Clark Trader: The Currency Trading Retirement Blueprint
  • Jason Williams Blue Gas: The Tesla Killer Fuel Cell Revolution
  • Andrew Zatlin: Biden’s Puppet Master Exposed and How to Opt Out of the Digital Dollar
  • The AI Takeover: Jason Bodner’s Quantum Edge Trader Smart Tech

Topics

AAPL Advertorial Amazon AMZN Artificial Intelligence Battery Bear Market Biotech Bitcoin Blockchain Clean Energy Cloud Computing Coronavirus COVID Creative Cryptocurrency Dividends E-Commerce Electric Vehicles Elon Musk Energy Ethereum Gold Growth Stocks Inflation Interest Rates International Jeff Brown Louis Navellier Market Crash MSFT Oil and Gas Options Prediction President Biden Recession Retirement Russia Semiconductor Supply Chain Tesla The Fed TSLA Volatility Warren Buffett

Copyright © 2023 · Stock Trend Alerts - Essential Market Moves and Investing Ideas

Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.

Stock Trend Alerts, its managers, its employees, affiliates and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above.

The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. The Company is not affiliated with, nor does it receive compensation from, any specific security.

To the maximum extent permitted by law, the Company disclaims any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses.

About Us | How it Works | Privacy Policy | Terms and Conditions | Contact Us